Bio-Rad Labs (BIO) Tops Q2 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bio-Rad Reports Second-Quarter 2018 Financial Results
August 7, 2018 4:49 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2018.
Second-quarter 2018 net sales were $575.9 million, an increase of 14.1 percent compared to $504.7 million reported for the second quarter of 2017. On a currency-neutral basis, quarterly sales increased 11.0 percent compared to the same period in 2017, reflecting broad growth across the business. Second-quarter gross margin was 52.4 percent compared to 54.2 percent during the second quarter in 2017. The decline in gross margin versus the same period last year is the... More
